Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.
Triple-negative breast cancer is a high-risk breast cancer with poor survival rate. To date, there is a lack of targeted therapy for this type of cancer. One unique phenomenon is that inflammatory breast cancer is frequently triple negative. However, it is still ambiguous how inflammation influences...
Main Authors: | Zining Jin, Wenqian Wang, Nan Jiang, Lei Zhang, Yiming Li, Xiaoyin Xu, Shouliang Cai, Liang Wei, Xuhong Liu, Guanglei Chen, Yizhen Zhou, Cheng Liu, Zhan Li, Feng Jin, Bo Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4510059?pdf=render |
Similar Items
-
Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders
by: Po-Han Lin, et al.
Published: (2022-12-01) -
Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
by: Wei Zhang, et al.
Published: (2023-04-01) -
Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
by: Yuxiang Lin, et al.
Published: (2022-08-01) -
Integrative Bioinformatics Analysis of iNOS/NOS2 in gastric and colorectal cancer
by: Lu Mingbei, et al.
Published: (2020-12-01) -
Targeting iNOS to increase efficacy of immunotherapies
by: Suhendan Ekmekcioglu, et al.
Published: (2017-05-01)